B-intervention	0	12	Prophylactic
I-intervention	13	24	irradiation
O	25	27	to
O	28	31	the
O	32	45	contralateral
O	46	52	breast
O	53	56	for
O	57	61	BRCA
O	62	70	mutation
O	71	79	carriers
O	80	84	with
O	85	90	early
O	90	91	-
O	91	96	stage
O	97	103	breast
O	104	110	cancer
O	110	111	.

O	112	117	Women
O	118	121	who
O	122	127	carry
O	128	132	germ
O	132	133	-
O	133	137	line
O	138	147	mutations
O	148	150	in
O	151	156	BRCA1
O	156	157	/
O	157	158	2
O	159	162	are
O	163	165	at
O	166	170	very
O	171	175	high
O	176	180	risk
O	181	183	of
O	184	194	developing
O	195	201	breast
O	202	205	and
O	206	213	ovarian
O	214	220	cancer
O	220	221	.

O	222	228	Breast
O	229	239	conserving
O	240	247	therapy
O	248	250	is
O	251	261	associated
O	262	266	with
O	267	268	a
O	269	276	similar
O	277	281	risk
O	282	284	of
O	285	296	ipsilateral
O	297	303	cancer
O	304	314	recurrence
O	315	317	in
O	318	322	BRCA
O	323	331	carriers
O	332	340	compared
O	341	345	with
O	346	349	non
O	349	350	-
O	350	358	carriers
O	358	359	.

O	360	367	However
O	367	368	,
O	369	372	the
O	373	377	risk
O	378	380	of
O	381	391	subsequent
O	392	405	contralateral
O	406	412	breast
O	413	419	cancer
O	420	422	in
O	423	431	carriers
O	432	434	is
O	435	443	markedly
O	444	453	increased
O	453	454	.

O	455	464	Therefore
O	464	465	,
O	466	476	mastectomy
O	477	479	of
O	480	483	the
O	484	492	diseased
O	493	499	breast
O	500	505	along
O	506	510	with
O	511	515	risk
O	516	524	reducing
O	525	535	mastectomy
O	536	538	of
O	539	542	the
O	543	556	contralateral
O	557	563	breast
O	564	566	is
O	567	572	often
O	573	582	advocated
O	583	586	for
O	587	591	BRCA
O	592	600	carriers
O	601	604	who
O	605	608	are
O	609	616	treated
O	617	620	for
O	621	626	early
O	627	633	breast
O	634	640	cancer
O	640	641	.

O	642	645	Yet
O	645	646	,
O	647	651	many
O	652	656	BRCA
O	657	665	carriers
O	666	671	forgo
O	672	676	this
O	677	683	option
O	684	687	for
O	688	692	fear
O	693	695	of
O	696	703	harmful
O	704	711	effects
O	712	715	and
O	716	722	choose
O	723	729	breast
O	730	740	conserving
O	741	750	treatment
O	751	754	and
O	755	766	observation
O	767	774	instead
O	774	775	.

O	776	778	In
O	779	785	Israel
O	785	786	,
O	787	791	BRCA
O	791	792	-
O	792	802	associated
O	803	809	breast
O	810	816	cancer
O	817	819	is
O	820	830	relatively
O	831	837	common
O	837	838	.

O	839	850	Accordingly
O	850	851	,
O	852	853	a
O	854	862	national
O	863	871	protocol
O	872	875	was
O	876	883	devised
O	884	887	for
O	888	892	this
O	893	901	enriched
O	902	912	population
O	912	913	.

O	914	916	In
O	917	921	this
O	922	935	Institutional
O	936	942	Review
O	943	948	Board
O	948	949	-
O	949	957	approved
O	958	963	phase
O	964	966	II
O	967	972	trial
O	972	973	,
O	974	977	the
O	978	984	option
O	985	987	of
O	988	1000	prophylactic
O	1001	1012	irradiation
O	1013	1015	to
O	1016	1019	the
O	1020	1033	contralateral
O	1034	1040	breast
O	1040	1041	,
O	1042	1044	in
O	1045	1053	addition
O	1054	1056	to
O	1057	1065	standard
O	1066	1070	loco
O	1070	1071	-
O	1071	1079	regional
O	1080	1089	treatment
O	1089	1090	,
O	1091	1094	was
O	1095	1102	offered
O	1103	1105	to
B-eligibility	1106	1110	BRCA
I-eligibility	1111	1118	carrier
I-eligibility	1119	1127	patients
I-eligibility	1128	1135	treated
I-eligibility	1136	1139	for
I-eligibility	1140	1145	early
I-eligibility	1146	1152	breast
I-eligibility	1153	1159	cancer
O	1160	1163	who
O	1164	1172	declined
O	1173	1186	contralateral
O	1187	1197	mastectomy
O	1197	1198	.

O	1199	1202	The
O	1203	1210	primary
O	1211	1214	end
O	1215	1220	point
O	1221	1224	was
B-outcome-Measure	1225	1238	contralateral
I-outcome-Measure	1239	1245	breast
I-outcome-Measure	1246	1252	cancer
O	1252	1253	.

O	1254	1261	Between
O	1262	1265	May
O	1266	1270	2007
O	1271	1274	and
O	1275	1282	October
O	1283	1287	2017
O	1287	1288	,
B-total-participants	1289	1292	162
O	1293	1301	patients
O	1302	1306	were
O	1307	1315	enrolled
O	1315	1316	.

B-control-participants	1317	1323	Eighty
I-control-participants	1323	1324	-
I-control-participants	1324	1327	one
O	1328	1336	patients
O	1337	1342	opted
O	1343	1346	for
O	1347	1355	standard
O	1356	1360	loco
O	1360	1361	-
O	1361	1369	regional
O	1370	1379	treatment
O	1380	1389	including
O	1390	1397	surgery
O	1398	1401	and
O	1402	1411	radiation
O	1412	1414	to
O	1415	1418	the
O	1419	1427	involved
O	1428	1432	side
O	1433	1434	(
B-control	1434	1441	control
I-control	1442	1445	arm
O	1445	1446	)
O	1447	1450	and
B-intervention-participants	1451	1453	81
O	1454	1462	patients
O	1463	1468	chose
O	1469	1479	additional
O	1480	1493	contralateral
O	1494	1500	breast
O	1501	1512	irradiation
O	1513	1514	(
O	1514	1526	intervention
O	1527	1530	arm
O	1530	1531	)
O	1531	1532	.

O	1533	1535	At
O	1536	1537	a
O	1538	1544	median
O	1545	1551	follow
O	1551	1552	-
O	1552	1554	up
O	1555	1557	of
O	1558	1560	58
O	1561	1567	months
O	1567	1568	,
B-iv-bin-abs	1569	1571	10
O	1572	1580	patients
O	1581	1590	developed
B-outcome	1591	1604	contralateral
I-outcome	1605	1611	breast
I-outcome	1612	1618	cancer
O	1619	1621	in
O	1622	1625	the
O	1626	1633	control
O	1634	1637	arm
O	1638	1640	at
O	1641	1642	a
O	1643	1649	median
O	1650	1652	of
O	1653	1655	32
O	1656	1662	months
O	1662	1663	,
O	1664	1666	as
O	1667	1675	compared
O	1676	1680	with
B-cv-bin-abs	1681	1682	2
O	1683	1691	patients
O	1692	1694	in
O	1695	1698	the
O	1699	1711	intervention
O	1712	1715	arm
O	1716	1719	who
O	1720	1729	developed
O	1730	1743	contralateral
O	1744	1750	breast
O	1751	1757	cancer
O	1758	1760	80
O	1761	1764	and
O	1765	1768	105
O	1769	1775	months
O	1776	1781	after
O	1782	1791	bilateral
O	1792	1798	breast
O	1799	1810	irradiation
O	1811	1812	(
O	1812	1815	log
O	1815	1816	-
O	1816	1820	rank
O	1821	1822	P
O	1823	1824	=
O	1825	1826	0
O	1826	1827	.
O	1827	1830	011
O	1830	1831	)
O	1831	1832	.

O	1833	1838	Among
O	1839	1843	BRCA
O	1844	1851	carrier
O	1852	1860	patients
O	1861	1868	treated
O	1869	1872	for
O	1873	1878	early
O	1879	1885	breast
O	1886	1892	cancer
O	1892	1893	,
O	1894	1897	the
O	1898	1906	addition
O	1907	1909	of
O	1910	1923	contralateral
O	1924	1930	breast
O	1931	1942	irradiation
O	1943	1946	was
O	1947	1957	associated
O	1958	1962	with
O	1963	1964	a
O	1965	1976	significant
O	1977	1986	reduction
O	1987	1989	of
O	1990	2000	subsequent
O	2001	2014	contralateral
O	2015	2021	breast
O	2022	2029	cancers
O	2030	2033	and
O	2034	2035	a
O	2036	2041	delay
O	2042	2044	in
O	2045	2050	their
O	2051	2056	onset
O	2056	2057	.

O	2058	2063	Phase
O	2064	2066	II
O	2066	2067	,
O	2068	2079	comparative
O	2080	2083	two
O	2083	2084	-
O	2084	2087	arm
O	2088	2093	trial
O	2094	2095	(
O	2095	2106	NCT00496288
O	2106	2107	)
O	2107	2108	.
